GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 8,746 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 8,746 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $95.61, for a total transaction of $836,205.06. Following the completion of the sale, the chief financial officer now owns 15,996 shares of the company’s stock, valued at $1,529,377.56. The trade was a 35.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The stock was sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Stock Performance

GeneDx stock opened at $92.20 on Friday. GeneDx Holdings Corp. has a 52-week low of $8.53 and a 52-week high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock has a fifty day moving average price of $87.28 and a two-hundred day moving average price of $73.92. The firm has a market capitalization of $2.59 billion, a P/E ratio of -47.04 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66. The firm had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the subject of a number of recent research reports. The Goldman Sachs Group upped their target price on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen upped their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $72.33.

Institutional Trading of GeneDx

Several large investors have recently made changes to their positions in the business. William Blair Investment Management LLC acquired a new position in GeneDx during the 4th quarter worth about $51,496,000. Lord Abbett & CO. LLC bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $48,458,000. Summit Partners Public Asset Management LLC increased its holdings in shares of GeneDx by 336.9% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock valued at $58,073,000 after purchasing an additional 582,619 shares in the last quarter. Science & Technology Partners L.P. bought a new position in GeneDx in the 4th quarter worth approximately $30,821,000. Finally, Fred Alger Management LLC acquired a new position in GeneDx during the 3rd quarter worth $16,731,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.